Liver function study aims to guide dosing of new antifungal drug

NCT ID NCT05582187

First seen Oct 31, 2025 · Last updated May 15, 2026 · Updated 26 times

Summary

This study looked at how a single dose of the antifungal drug fosmanogepix is handled by the body in 28 adults with varying degrees of liver impairment. Participants took one pill, and researchers measured drug levels in the blood over time. The goal was to understand if liver function affects drug clearance and safety, which helps doctors decide on proper dosing for patients with liver issues.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATIC IMPAIRMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Genesis Clinical Research, LLC

    Tampa, Florida, 33603, United States

  • Inland Empire Liver Foundation

    Rialto, California, 92337, United States

Conditions

Explore the condition pages connected to this study.